

Author index

Volume 59 (2003)

- Aldern, K.A., see Ciesla, S.L. **59**, 163
- Armand-Ugón, M., A. Gutiérrez, B. Clotet, J.A. Esté, HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 **59**, 137
- Bastow, K.F., see Lowden, C.T. **59**, 143
- Baum, E.Z., P.C. Wagaman, L. Ly, I. Turchi, J. Le, D. Bucher, K. Bush, A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding **59**, 13
- Beadle, J.R., see Ciesla, S.L. **59**, 163
- Blumberg, P.M., see Bocklandt, S. **59**, 89
- Bocklandt, S., P.M. Blumberg, D.H. Hamer, Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate **59**, 89
- Bolger, G.T., see Garneau, M. **59**, 193
- Bonville, C.A., see Moreau, J.M. **59**, 181
- Bousquet, C., see Garneau, M. **59**, 193
- Bucher, D., see Baum, E.Z. **59**, 13
- Bush, K., see Baum, E.Z. **59**, 13
- Chang, W.-Y., see Yu, M.-L. **59**, 35
- Chen, C.-J., see Yu, M.-L. **59**, 35
- Chen, S.-C., see Yu, M.-L. **59**, 35
- Chiu, C.-C., see Yu, M.-L. **59**, 35
- Chuang, W.-L., see Yu, M.-L. **59**, 35
- Ciesla, S.L., J. Trahan, W.B. Wan, J.R. Beadle, K.A. Aldern, G.R. Painter, K.Y. Hostetler, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney **59**, 163
- Clotet, B., see Armand-Ugón, M. **59**, 137
- Colunno, R.J., see Julander, J.G. **59**, 155
- Compans, R.W., see Vzorov, A.N. **59**, 99
- Cordingley, M.G., see Garneau, M. **59**, 193
- Cousins, S.W., see Dix, R.D. **59**, 111
- Dai, C.-Y., see Yu, M.-L. **59**, 35
- De Clercq, E., see Helliot, B. **59**, 121
- Dekhtyar, T., see Mo, H. **59**, 173
- Devadas, K., P. Zhou, D. Tewari, A.L. Notkins, Inhibition of HIV-1 replication by the combined action of anti-gp41 single chain antibody and IL-16 **59**, 67
- Dix, R.D., E.R. Podack, S.W. Cousins, Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA **59**, 111
- Dixon, D.W., see Vzorov, A.N. **59**, 99
- Domachowske, J.B., see Moreau, J.M. **59**, 181
- Dyer, K.D., see Moreau, J.M. **59**, 181
- Easton, A.J., see Moreau, J.M. **59**, 181
- Engels, M., see Oevermann, A. **59**, 23
- Esté, J.A., see Armand-Ugón, M. **59**, 137
- Frison, E., see Helliot, B. **59**, 121
- Fuchuan, L., see Meiyu, G. **59**, 127
- Garneau, M., G.T. Bolger, C. Bousquet, P. Kibler, F. Tremblay, M.G. Cordingley, HPMPD therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique **59**, 193
- Gutiérrez, A., see Armand-Ugón, M. **59**, 137
- Hamer, D.H., see Bocklandt, S. **59**, 89
- Helliot, B., B. Panis, E. Frison, E. De Clercq, R. Swennen, P. Lepoivre, J. Neyts, The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (*Musa* spp.) **59**, 121
- Hostetler, K.Y., see Ciesla, S.L. **59**, 163
- Hsieh, M.-Y., see Yu, M.-L. **59**, 35
- Huashi, G., see Meiyu, G. **59**, 127
- Jing, L., see Meiyu, G. **59**, 127
- Julander, J.G., R.J. Colunno, R.W. Sidwell, J.D. Morrey, Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus **59**, 155
- Kempf, D.J., see Mo, H. **59**, 173
- Kibler, P., see Garneau, M. **59**, 193
- Le, J., see Baum, E.Z. **59**, 13
- Lee, L.-P., see Yu, M.-L. **59**, 35
- Lepoivre, P., see Helliot, B. **59**, 121
- Lin, J.-C., Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro **59**, 41
- Lin, Z.-Y., see Yu, M.-L. **59**, 35
- Lowden, C.T., K.F. Bastow, Cell culture replication of herpes simplex virus and, or human cytomegalovirus is inhibited by 3,7-dialkoxyated, 1-hydroxyacridone derivatives **59**, 143
- Lu, L., see Mo, H. **59**, 173
- Ly, L., see Baum, E.Z. **59**, 13
- Marzilli, L.G., see Vzorov, A.N. **59**, 99
- Meiyu, G., L. Fuchuan, X. Xianliang, L. Jing, Y. Zuowei, G. Huashi, The potential molecular targets of marine sulfated polymannuronate interfering with HIV-1 entry. Interaction between SPMG and HIV-1 rgp120 and CD4 molecule **59**, 127
- Mo, H., L. Lu, T. Dekhtyar, K.D. Stewart, E. Sun, D.J. Kempf, A. Molla, Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir **59**, 173
- Molla, A., see Mo, H. **59**, 173
- Moreau, J.M., K.D. Dyer, C.A. Bonville, T. Nitto, N.L. Vasquez, A.J. Easton, J.B. Domachowske, H.F. Rosenberg, Diminished expression of

- an antiviral ribonuclease in response to pneumovirus infection in vivo **59**, 181
- Morrey, J.D., see Julander, J.G. **59**, 155
- Neyts, J., see Helliot, B. **59**, 121
- Nitto, T., see Moreau, J.M. **59**, 181
- Notkins, A.L., see Devadas, K. **59**, 67
- Oevermann, A., M. Engels, U. Thomas, A. Pellegrini, The antiviral activity of naturally occurring proteins and their peptide fragments after chemical modification **59**, 23
- Painter, G.R., see Ciesla, S.L. **59**, 163
- Panis, B., see Helliot, B. **59**, 121
- Pawlotsky, J.-M., Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C **59**, 1
- Pellegrini, A., see Oevermann, A. **59**, 23
- Podack, E.R., see Dix, R.D. **59**, 111
- Rosenberg, H.F., see Moreau, J.M. **59**, 181
- Si, L., see Zheng, J. **59**, 61
- Sidwell, R.W., see Julander, J.G. **59**, 155
- Song, J., see Zheng, J. **59**, 61
- Stewart, K.D., see Mo, H. **59**, 173
- Sun, E., see Mo, H. **59**, 173
- Sun, X., see Zheng, J. **59**, 61
- Swennen, R., see Helliot, B. **59**, 121
- Tewari, D., see Devadas, K. **59**, 67
- Thomas, U., see Oevermann, A. **59**, 23
- Trahan, J., see Ciesla, S.L. **59**, 163
- Tremblay, F., see Garneau, M. **59**, 193
- Turchi, I., see Baum, E.Z. **59**, 13
- van Zeijl, M., see Visalli, R.J. **59**, 73
- Vasquez, N.L., see Moreau, J.M. **59**, 181
- Visalli, R.J., , M. van Zeijl, DNA encapsidation as a target for anti-herpesvirus drug therapy **59**, 73
- Vzorov, A.N., L.G. Marzilli, R.W. Compans, D.W. Dixon, Prevention of HIV-1 infection by phthalocyanines **59**, 99
- Wagaman, P.C., see Baum, E.Z. **59**, 13
- Wan, W.B., see Ciesla, S.L. **59**, 163
- Wang, L.-Y., see Yu, M.-L. **59**, 35
- Wang, Y., see Zheng, J. **59**, 61
- Wassilew, S.W., , P. Wutzler, Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia **59**, 57
- Wassilew, S.W., , P. Wutzler, Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study **59**, 49
- Wutzler, P., see Wassilew, S.W. **59**, 49, 57
- Xianliang, X., see Meiyu, G. **59**, 127
- Yu, J., see Zheng, J. **59**, 61
- Yu, M.-L., C.-Y. Dai, C.-C. Chiu, L.-P. Lee, Z.-Y. Lin, S.-C. Chen, M.-Y. Hsieh, L.-Y. Wang, C.-J. Chen, W.-L. Chuang, W.-Y. Chang, Tumor necrosis factor α promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha **59**, 35
- Zheng, J., L. Si, J. Song, X. Sun, J. Yu, Y. Wang, Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2 **59**, 61
- Zhou, P., see Devadas, K. **59**, 67
- Zuowei, Y., see Meiyu, G. **59**, 127